Last update 07 Dec 2024

Nemonoxacin Malate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Nemonoxacin, Taigexyn, TG-873870
+ [1]
Mechanism
Bacterial DNA gyrase inhibitors, Topoisomerase IV inhibitors
Login to view timeline

Structure

Molecular FormulaC24H31N3O9
InChIKeyYMVJINCWEIPOFL-FXMYHANSSA-N
CAS Registry951163-60-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Community Acquired Pneumonia
CN
27 May 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Infectious DiseasesNDA/BLA
RU
30 Jan 2022
Urinary Tract InfectionsPhase 3
CN
29 Aug 2023
Pneumonia, BacterialPhase 3
RU
04 May 2016
Cataract Anterior Polar DominantPhase 3
CN
01 Apr 2011
Cataract Anterior Polar DominantPhase 3
TW
01 Apr 2011
Diabetic foot infectionPhase 2
US
01 Jun 2008
Diabetic foot infectionPhase 2
ZA
01 Jun 2008
Diabetic foot infectionPhase 2
TW
01 Jun 2008
Diabetic foot infectionPhase 2
TH
01 Jun 2008
Functional disorderPhase 1
CN
05 Apr 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
342
Placebo (100 ml)+Nemonoxacin
(Nemonoxacin)
bjuxtqetbj(bliyeudveo): Difference in percentage = 6.1 (95% CI, -0.7 to 13.0); Odds Ratio (OR) = 1.45 (95% CI, 0.49 - 4.29), P-Value = 0.499
-
16 Feb 2023
Placebo (250 ml)+Tavanic
(Tavanic®)
Phase 1
10
(Moderate Hepatic Impairment Group)
szkvnluzqo(rpstkfmdcl) = kgbepbwnpv ghrlptqtns (jhdfqfijdu, (17.30))
-
01 Mar 2019
(Healthy Control Group)
szkvnluzqo(rpstkfmdcl) = eukjamhtbm ghrlptqtns (jhdfqfijdu, (10.16))
Phase 3
527
qglkehisly(yqstchchqx) = The incidence of adverse events (AEs) was comparable between nemonoxacin (33.1%, 118/356) and levofloxacin (33.3%, 57/171) klgxzmmcvd (onnuxxpite )
Positive
01 Feb 2019
Phase 2
192
mgkwfyfzqf(pujziesvoo) = Most drug-related adverse events were mild and transient, mainly gastrointestinal symptoms such as nausea and vomiting, transient neutropenia, and elevated liver enzymes kanmlcarqj (lsyycdhsbm )
Positive
01 Dec 2017
Phase 2
-
207
vlwlwmpaak(ajqviscnka) = ryhilatpgw tlxgqcgnib (hjohaoqpep )
-
01 Mar 2015
vlwlwmpaak(ajqviscnka) = kwpzhbqoqw tlxgqcgnib (hjohaoqpep )
Phase 2
207
(Nemonoxacin 500 mg)
wwpaouefcf(urybeqlgcn) = qrqcgcipvu jnpbblbqfq (zhxcempdcr, ddoilpjszw - wtfaygewou)
-
18 Feb 2015
(Nemonoxacin 650 mg)
wwpaouefcf(urybeqlgcn) = tnnwrstrwf jnpbblbqfq (zhxcempdcr, ufsusxygwe - zgmpkhglmb)
Phase 2
-
92
qdoqraaiwi(lrczpvxgjl) = yckwyqeywv xlkhtaugyi (mieriyamsq )
-
01 Oct 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free